Back to Search
Start Over
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
- Source :
- Scientific Reports, Vol 10, Iss 1, Pp 1-7 (2020), Scientific Reports
- Publication Year :
- 2020
- Publisher :
- Nature Publishing Group, 2020.
-
Abstract
- The efficacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients with recurrent or advanced non-small cell lung cancer (NSCLC) in a real-world setting. This study included patients with recurrent or advanced NSCLC diagnosed between September 1, 2015 and August 31, 2019, who were treated with programmed cell death 1 (PD-1) inhibitors at the Cancer Center of the Chinese People’s Liberation Army. PFS was estimated for each treatment group using Kaplan–Meier curves and log-rank tests. The multivariate analysis of PFS was performed with Cox proportional hazards regression models. A total of 255 patients with advanced or recurrent NSCLC treated with PD-1 inhibitors were identified. The ORR was significantly higher in the pembrolizumab group than in the nivolumab group, while PFS was not significantly different between the two groups. Subgroup analysis showed that the ORR was significantly higher for pembrolizumab than for nivolumab in patients in the first-line therapy subgroup and in those in the combination therapy as first-line therapy subgroup. Survival analysis of patients receiving combination therapy as second- or further-line therapy showed that nivolumab had better efficacy than pembrolizumab. However, the multivariate analysis revealed no significant difference in PFS between patients treated with pembrolizumab and those treated with nivolumab regardless of the subgroup. In our study, no significant difference in PFS was noted between patients treated with pembrolizumab and those treated with nivolumab in various clinical settings. This supports the current practice of choosing either pembrolizumab or nivolumab based on patient preferences.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
China
medicine.medical_specialty
Lung Neoplasms
Multivariate analysis
Combination therapy
lcsh:Medicine
Cancer immunotherapy
Drug development
Subgroup analysis
Pembrolizumab
Antibodies, Monoclonal, Humanized
Article
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
Internal medicine
medicine
Humans
In patient
lcsh:Science
Survival analysis
Aged
Retrospective Studies
Aged, 80 and over
Multidisciplinary
business.industry
lcsh:R
Cancer
Middle Aged
medicine.disease
Survival Analysis
Nivolumab
Treatment Outcome
030104 developmental biology
Female
lcsh:Q
business
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 20452322
- Volume :
- 10
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....2f2fc4618425f937da2a544fc8a2234e